Krystal Biotech has demonstrated sustained momentum over the past three months, clearing our Recent Price Strength screen by outperforming 75% of its peers in the biotechnology sector. Trading volume has risen by 30% on average during this period, signaling increased institutional interest. Technical indicators show the stock consistently making higher highs and higher lows, while relative strength has remained above the 70 threshold, underscoring its bullish price trajectory.

Over the past 12 months, Krystal Biotech’s shares have climbed 57%, driven primarily by robust uptake of Vyjuvek, its FDA-approved gene therapy for epidermolysis bullosa. Quarterly Vyjuvek prescriptions climbed by 45% year-over-year, reaching over 600 new patients in the latest reporting period. Additionally, operating expenses declined by 12% sequentially as manufacturing efficiencies scaled, contributing to an improved gross margin of 68%.

Looking ahead to 2026, management projects double-digit revenue growth as Vyjuvek continues market penetration in Europe, where regulatory filings are slated for mid-year. Concurrently, two preclinical programs targeting rare skin disorders have entered Phase 1 studies, with topline data expected in Q3. Cash reserves stood at $250 million at year-end, sufficient to fund operations through peak clinical milestones without additional equity raises.